Search alternatives:
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
-
13641
-
13642
-
13643
<i>l</i>-THP decreased level of NO, ONOO<sup>−</sup> and iNOS, regulated expression of p85, eNOS and Akt.
Published 2013“…(<b>g</b>) iNOS expression of myocardial I/R rats treated with vehicle and <i>l</i>-THP (M). iNOS expression was significantly decreased in <i>l</i>-THP (M)-treated group, <sup>###</sup>P<0.001 vs. sham group, *P<0.05 vs. vehicle group, n = 5. …”
-
13644
Simultaneous ablation of Syt1 and Syt7 decreases the RRP size at inhibitory synapses: Rescue by WT but not mutant Syt1 or Syt7.
Published 2015“…Recordings were performed in the presence of 1 μM tetrodotoxin, 20 μM CNQX, and 50 μM AP5 to isolate inhibitory currents. <b>B.</b> Simultaneous ablation of Syt1 and Syt7 decreases the RRP size of inhibitory synapses in a manner that is rescued by WT Syt7 (Syt1<sup>WT</sup>) but not Syt7 with mutations in the top C2 domain sequences containing the Syt7 Ca<sup>2+</sup> binding sites (Syt7<sup>C2A</sup>*<sup>B</sup>*). …”
-
13645
-
13646
-
13647
-
13648
Silencing GRK2 and GRK3 attenuate C3aR desensitization but GRK5 and GRK6 do not.
Published 2013“…<p>(A) shRNA control, (B) GRK2, (C) GRK3, (D) GRK5 and (E) GRK6 KD cells were loaded with Indo-1 (1 µM), stimulated with C3a (100 nM) for 5 min and intracellular Ca<sup>2+</sup> mobilization was determined (black solid lines). …”
-
13649
-
13650
-
13651
-
13652
Long-term health status and trajectories of seriously injured patients: A population-based longitudinal study
Published 2017“…We followed up 2,757 adult patients, injured between July 2011 and June 2012, through deaths registry linkage and telephone interview at 6-, 12-, 24-, and 36-months postinjury. The 3-level EuroQol 5 dimensions questionnaire (EQ-5D-3L) was collected, and mixed-effects regression modelling was used to identify predictors of outcome, and recovery trajectories, for the EQ-5D-3L items and summary score. …”
-
13653
-
13654
Median confidence factor at the end of the simulation decreases as war costs increase (line represents the median of 200 simulations for each level of war costs).
Published 2011“…Note, however, that this decrease would be offset by altering other settings of the model, such as increasing the attack threshold, <i>w</i>, above 0.5, or allowing the spoils of victory to exceed the losses of defeat, instead of the current setup in which there is a zero-sum gain or loss of a province.…”
-
13655
-
13656
Data_Sheet_1_A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.PDF
Published 2023“…/mL (IQR 285.4) (p = 0.05); serum month 24: 6.7 pg/mL (IQR 4.7) (p < 0.01); serum month 60: 7.2 pg/mL (IQR 4.7) (p < 0.01)], compared to baseline [CSF: 1014 pg/mL (IQR 2832.5); serum 8.6 pg/mL (IQR 17.4)].</p>Conclusion<p>In this real-world mono-center population, we observed a progression-free survival of 69%, cumulative NEDA-3 of 33%, and reduced NfL levels, over a five-year follow-up. …”
-
13657
-
13658
-
13659
Table_1_Open-Label Placebo Administration Decreases Pain in Elderly Patients With Symptomatic Knee Osteoarthritis – A Randomized Controlled Trial.pdf
Published 2022“…</p>Trial Registration<p>German Clinical Trials Register (https://www.drks.de/), DRKS00015191 (retrospectively registered).…”
-
13660